If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
== Enforcement == Within the European Union GMP inspections are performed by National Regulatory Agencies. GMP inspections are performed in Canada by the Health Products and Food Branch Inspectorate; in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA); in the Republic of Korea (South Korea) by the Ministry of Food and Drug Safety (MFDS); in Australia by the Therapeutic Goods Administration (TGA); in Bangladesh by the Directorate General of Drug Administration (DGDA); in South Africa by the Medicines Control Council (MCC); in Brazil by the National Health Surveillance Agency (ANVISA); in India by state Food and Drugs Administrations (FDA), reporting to the Central Drugs Standard Control Organization; in Pakistan by the Drug Regulatory Authority of Pakistan; in Nigeria by NAFDAC; and by similar national organizations worldwide. Each of the inspectorates carries out routine GMP inspections to ensure that drug products are produced safely and correctly. Additionally, many countries perform pre-approval inspections (PAI) for GMP compliance prior to the approval of a new drug for marketing.
Homochirality is the uniformity of materials composed of chiral (non-mirror-symmetric) units. Living organisms use molecules with the same chirality: with almost no exceptions, amino acids are left-handed while nucleotides and sugars are right-handed. Chiral molecules can be synthesized, but in the absence of a chiral source or a chiral catalyst, they are formed in a 50/50 (racemic) mixture of both forms. Non-racemic mixtures can arise from racemic materials by asymmetric physical laws such as the electroweak interaction, or in asymmetric environments, such as those in which molecules are exposed to circularly polarized light of a given handedness. It has been hypothesized that the solar nebula was such an environment, exposed to circularly-polarized radiation from an external source before or during the epoch of planet formation. This proposal is consistent with the finding that some amino acids delivered to Earth in meteorites exhibit a chiral asymmetry of the same sign as terrestrial life. Once established, a chirality imbalance may influence subsequent chemical evolution. A small bias in the population can be amplified by asymmetric autocatalysis, as in the Soai reaction, where a chiral molecule catalyzes its own production.
Although elastin is exceptionally long-lived, its structure and function can change with aging. In human skin, aging has been associated with reductions and structural alterations in dermal elastin and elastic fibers. Imaging studies have reported age-related changes in the amount and organization of dermal elastin, including fragmentation and reduced connectivity of elastic-fiber networks. These changes may contribute to the decline in skin elasticity and firmness associated with aging.
Natural fibers often show promise as biomaterials in medical applications. Chitin is notable in particular and has been incorporated into a variety of uses. Chitin based materials have also been used to remove industrial pollutants from water, processed into fibers and films, and used as biosensors in the food industry. Chitin has also been used several of medical applications. It has been incorporated as a bone filling material for tissue regeneration, a drug carrier and excipient, and as an antitumor agent. Insertion of foreign materials into the body often triggers an immune response, which can have a variety of positive or negative outcomes depending on the bodies response to the material. Implanting something made from naturally synthesized proteins, such as a keratin based implant, has the potential to be recognized as natural tissue by the body. This can lead either to integration in rare cases where the structure of the implant promotes regrowth of tissue with the implant forming a superstructure or degradation of the implant in which the backbones of the proteins are recognized for cleavage by the body.
Sources: en.wikipedia.org
== Production == The production methods for different isotopes vary, and only those for promethium-147 are given because it is the only isotope with industrial applications. Promethium-147 is produced in large quantities (compared to other isotopes) by bombarding uranium-235 with thermal neutrons. The output is relatively high, at 2.6% of the total product. Another way to produce promethium-147 is via neodymium-147, which decays to promethium-147 with a short half-life. Neodymium-147 can be obtained either by bombarding enriched neodymium-146 with thermal neutrons or by bombarding a uranium carbide target with energetic protons in a particle accelerator. Another method is to bombard uranium-238 with fast neutrons to cause fast fission, which, among multiple reaction products, creates promethium-147. As early as the 1960s, Oak Ridge National Laboratory could produce 650 grams of promethium per year and was the world's only large-volume synthesis facility. Gram-scale production of promethium was discontinued in the U.S. in the early 1980s, but will possibly be resumed after 2010 at the High Flux Isotope Reactor. In 2010, Russia was the only country producing promethium-147 on a relatively large scale.
== Reagan administration == President Ronald Reagan officially announced his war on drugs in October 1982. Reagan began to shift the job of drug enforcement from the state to the federal level. Reagan greatly increased the budgets of the antidrug programs in the FBI, the DEA, and the Department of Defense.
In 1939, Drew married Minnie Lenore Robbins, a professor of home economics at Spelman College in Atlanta, Georgia, whom he had met earlier during that year. They had three daughters and a son. His daughter Charlene Drew Jarvis served on Council of the District of Columbia from 1979 to 2000, was the president of Southeastern University from 1996 until 2009, and was a president of the District of Columbia Chamber of Commerce.
Breeding onset occurs at about 50 days of age in both females and males, although females may have their first estrus at 25–40 days. Mice are polyestrous and breed year round; ovulation is spontaneous. The duration of the estrous cycle is 4–5 days and lasts about 12 hours, occurring in the evening. Vaginal smears are useful in timed matings to determine the stage of the estrous cycle. Mating can be confirmed by the presence of a copulatory plug in the vagina up to 24 hours post-copulation. The presence of sperm on a vaginal smear is also a reliable indicator of mating. The average gestation period is 20 days. A fertile postpartum estrus occurs 14–24 hours following parturition, and simultaneous lactation and gestation prolongs gestation by 3–10 days, owing to delayed implantation. The average litter size is 10–12 during optimum production, but this is highly strain-dependent. In general, inbred mice tend to have longer gestation periods and smaller litters than outbred and hybrid mice. The young are called pups and weigh 0.5–1.5 g (0.018–0.053 oz) at birth, are hairless, and have closed eyelids and ears. Pups are weaned at 3 weeks of age, when they weigh about 10–12 g (0.35–0.42 oz). If the female does not mate during the postpartum estrus, she resumes cycling 2–5 days post-weaning. Newborn males are distinguished from newborn females by their greater anogenital distance and larger genital papilla. This is usually observed by lifting the tails of littermates and comparing perinea.
Moscow hosted the 1980 Summer Olympics; the yachting events were held in Tallinn, Estonia (then the Estonian Soviet Socialist Republic). Large sports facilities and the main international airport—Sheremetyevo Terminal 2—were constructed to prepare for the 1980 Summer Olympics. Moscow had previously bid for the 2012 Summer Olympics. However, when final voting began on 6 July 2005, Moscow was the first city to be eliminated; those Games were awarded to London. HC CSKA Moscow is the most titled ice hockey team in the Soviet Union and Europe. Other large ice hockey clubs from Moscow are HC Dynamo Moscow (which was the second most titled team in the Soviet Union) and HC Spartak Moscow. The most titled Soviet and Russian club—and one of the most titled Euroleague clubs—is the basketball club from Moscow, PBC CSKA Moscow. Moscow hosted the EuroBasket tournament in 1953 and 1965. Among competing cities, Moscow had the most winners at the USSR Chess Championship and the Russian Chess Championship. The most titled volleyball team in the Soviet Union and in Europe (the CEV Champions League) is VC CSKA Moscow. In football (also known as soccer), FC Spartak Moscow has won the most championship titles in the Russian Premier League. The team was second only to FC Dynamo Kyiv in Soviet times. PFC CSKA Moscow was the first Russian football team to win a UEFA title, the UEFA Cup (the contemporary UEFA Europa League). FC Lokomotiv Moscow, FC Dynamo Moscow, and FC Torpedo Moscow are other professional football teams that are based in Moscow.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.